Lung cancer trials in China

In China 1144 Also abroad 2746

1,144 trials · From ClinicalTrials.gov, checked 14 November 2026. Ask the study team whether a trial fits you.

Phase 2Not yet taking people in China
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC
Where
Xi'an
Age
18 years to 75 years
People
178
Run by
Tang-Du Hospital
See details and how to joinNCT06475755
No phaseTaking people
SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer
Where
Lianyungang
Age
18 years to 80 years
People
46
Run by
The First People's Hospital of Lianyungang
See details and how to joinNCT06476093
No phaseTaking people
iCAGES-guided Precision Therapy for Cancers in Contrast to Standard Care or IHC-guided Theray
Where
Guangzhou
Age
18 years to 70 years
People
250
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03192501
Phase 1Taking people
GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
Where
Guangzhou
Age
18 years to 75 years
People
30
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198052
Phase 1Taking people
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
Where
Guangzhou
Age
18 years to 75 years
People
30
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03198546
Phase 2/3Taking people
Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors
Where
Guanzhou
Age
18 years and over
People
200
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03755739
No phaseTaking people
Evaluating the Safety and Efficacy of Pembrolizumab Combined With MWA for Advanced NSCLC
Where
Guangzhou
Age
18 years and over
People
100
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03769129
Phase 1Taking people
TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors
Where
Guanzhou
Age
18 years to 75 years
People
30
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT03778814
Phase 2Taking people
Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors
Where
Guangzhou
Age
18 years to 85 years
People
100
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04803318
Phase 1Taking people
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
Where
Guangzhou
Age
18 years to 85 years
People
40
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT04842812
Early phase 1Taking people
Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC
Where
Guangzhou
Age
18 years to 75 years
People
11
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05060796
Phase 1/2Taking people
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
Where
Guangzhou
Age
18 years to 70 years
People
100
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05187338
Early phase 1Taking people
EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer
Where
Guangzhou
Age
18 years to 75 years
People
30
Run by
Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT05341492
Phase 2Taking people
A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy
Where
Yichang
Age
18 years to 75 years
People
48
Run by
Xin-Hua Xu
See details and how to joinNCT06467500
Phase 4Taking people
Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung Cancer
Where
Xi'an
Age
18 years and over
People
24
Run by
Tang-Du Hospital
See details and how to joinNCT06467786
Phase 2Taking people
Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)
Where
Shijiazhuang
Age
18 years to 75 years
People
58
Run by
Hebei Medical University Fourth Hospital
See details and how to joinNCT06371482
Phase 1/2Not yet taking people in China
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Where
Shanghai
Age
18 years to 75 years
People
60
Run by
Shanghai Chest Hospital
See details and how to joinNCT06456138
No phaseNot yet taking people in China
Efficacy and Safety of Multimode Thermal Therapy in the Treatment of Early Peripheral Lung Cancer
Where
Shanghai
Age
18 years and over
People
10
Run by
Shanghai Chest Hospital
See details and how to joinNCT06453889
Phase 2Taking people
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Where
Changsha
Age
18 years and over
People
760
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT05284539
Phase 2Taking people
Efficacy and Safety of Modified Si Jun Zi Tang in Perioperative NSCLC Treatment
Where
Hangzhou
Age
18 years to 75 years
People
60
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06445881
Phase 2/3Taking people
Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
Where
Changsha
Age
18 years and over
People
1,200
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT04322617
No phaseTaking people
Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer
Where
Changsha
Age
18 years and over
People
15,000
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT05059951
Phase 2Taking people
Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases
Where
Changsha
Age
18 years and over
People
220
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT06440954
Phase 3Taking people
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
Where
Shanghai
Age
18 years to 80 years
People
307
Run by
Fudan University
See details and how to joinNCT05717803
Phase 2Taking people
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
Where
Changsha
Age
18 years and over
People
78
Run by
Hunan Province Tumor Hospital
See details and how to joinNCT05266846